Pathophysiology-Driven Treatment for IBS-C

New Evidence Distills a Pathophysiology-Driven IBS-C Treatment Strategy

A comprehensive review published in Annals of Medicine offers a structured clinical approach for the millions of patients who experience constipation with bloating, a particularly distressing symptom combination. The authors, including Mayo Clinic and Cedars-Sinai experts, stress that bloating is not a simple side effect of constipation but a complex symptom with its own, sometimes overlapping, physiological roots. Successfully managing irritable bowel syndrome with constipation (IBS-C) now requires separating and targeting these distinct mechanisms.

Why Constipation Relief Alone Often Falls Short for Bloating

Drs. Cangemi, Chang, and colleagues clarify a central point: while constipation and bloating frequently coexist, one does not necessarily cause the other. Bloating arises from a mix of retained gas, impaired gas transit, heightened visceral sensitivity (where normal gas volumes feel painful), and abnormal abdominal muscle reflexes. Constipation treatments like bulk-forming fibers or osmotic laxatives may improve stool passage but can exacerbate gas and bloating in some individuals. This explains why a one-size-fits-all laxative approach often disappoints patients whose bloating persists. The review argues for a diagnostic evaluation that actively looks for conditions like pelvic floor dysfunction—where muscles fail to coordinate for a normal bowel movement—or intestinal methanogen overgrowth, a form of microbial overgrowth where archaea produce methane gas that slows gut transit.

Prescription Secretagogues Demonstrate Dual Symptom Efficacy

The Annals review highlights a class of prescription drugs as a cornerstone of modern IBS-C management. Agents like plecanatide, linaclotide, lubiprostone, and tenapanor are called secretagogues. They work directly on the intestinal lining to increase fluid secretion, which softens stool and accelerates its transit through the colon. Critically, multiple large, randomized controlled trials have shown these medications improve both constipation and bloating scores in patients with IBS-C. Their mechanism—increasing luminal fluid—may help flush out gas-producing substrates and reduce the colonic fermentation that contributes to bloating. For patients with significant bloating, this makes secretagogues a first-line pharmacological option over treatments that only address stool frequency.

Targeting Microbial Overgrowth with Antibiotics and Diet

When bloating is severe and disproportionate, research points to the small intestine as a key battleground. A separate 2026 analysis in Internal and Emergency Medicine by Iftequar, Goel, Chowdhary et al. examined targeted antibiotic use across IBS subtypes. For patients with constipation-predominant IBS and evidence of small intestinal bacterial overgrowth (SIBO) or intestinal methanogen overgrowth (IMO), a course of non-absorbable antibiotics like rifaximin (often with neomycin for methane) can directly reduce the gas-producing microbial population. The researchers emphasize this should be paired with a low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet. This dietary approach starves the remaining bacteria of their preferred fuel, providing a synergistic effect to reduce fermentation-derived gas and bloating. This combination represents a specific, pathophysiology-driven strategy distinct from general constipation management.

A Practical, Multi-Layered Management Framework

These reviews converge on a stepwise, personalized clinical strategy. Evaluation begins with distinguishing IBS-C from chronic idiopathic constipation and screening for pelvic floor dysfunction with anorectal manometry. If food triggers are suspected, a monitored trial of a low-FODMAP diet is recommended. For diagnosed pelvic floor dysfunction, the evidence supports pelvic floor physical therapy with biofeedback as the primary treatment, not laxatives. When SIBO or IMO is confirmed via breath testing, targeted antibiotics followed by a prokinetic agent and dietary modification form the core protocol. For core IBS-C symptoms, prescription secretagogues are the best-evidenced pharmacologic option. For refractory cases or those with prominent gut-brain axis components, the addition of neuromodulators like low-dose tricyclic antidepressants can help modulate visceral hypersensitivity and pain. As the Cedars-Sinai and Mayo Clinic authors conclude, “understanding the pathophysiology of bloating for an individual patient… will be paramount to improve treatment outcomes.”

Sources:
https://pubmed.ncbi.nlm.nih.gov/42319080/
https://pubmed.ncbi.nlm.nih.gov/42310284/